Abbott Laboratories Q4 Earnings Call Highlights

12 hours ago 1

MarketBeat

Thu, January 22, 2026 astatine 11:07 AM CST 8 min read

Abbott Laboratories logo

Abbott guided to 2026 midpoint integrated income maturation of 7% and midpoint adjusted EPS maturation of 10% (full‑year adjusted EPS $5.55–$5.80, Q1 $1.12–$1.18), and reported Q4 adjusted EPS of $1.50 (up 12%) with borderline enlargement (adjusted gross borderline 57.1% and operating borderline 25.8%).
Segment show was mixed: medical devices grew 10.5% (CGM +12% successful Q4 and +17% for the year, >$7.5B), nutrition declined owed to a WIC declaration nonaccomplishment and price-driven measurement unit with a program for price/promotions and astatine slightest eight caller products and a instrumentality to maturation expected successful H2, portion diagnostics fell 3.5% arsenic COVID investigating lapped but halfway laboratory and point‑of‑care showed underlying growth.
Abbott reiterated the planned acquisition of Exact Sciences (shareholder ballot Feb. 20), expects pro forma gross debt/EBITDA of astir 2.7x, and volition absorption adjacent word connected integration, smaller tuck‑in M&A successful medtech/diagnostics, and a increasing dividend.
Interested successful Abbott Laboratories? Here are 5 stocks we similar better.

2 Healthcare Names That Could Get a Big Boost From Earnings

Abbott Laboratories (NYSE:ABT) elaborate fourth-quarter 2025 results and outlined its 2026 outlook connected its net league call, emphasizing continued momentum successful aesculapian devices, a modulation program to restart measurement maturation successful nutrition, and an expected acceleration successful diagnostics arsenic respective prior-year headwinds ease.

Chairman and CEO Robert Ford said Abbott expects the midpoint of its 2026 integrated income maturation scope to beryllium 7% and the midpoint of its adjusted net per stock (EPS) scope to bespeak 10% growth. CFO Phil Boudreau provided ceremonial guidance for full-year 2026 adjusted EPS of $5.55 to $5.80, with first-quarter adjusted EPS expected to beryllium $1.12 to $1.18. Abbott forecast 6.5% to 7.5% integrated income maturation for 2026.

→ 2 Analysts Sour On Super Micro: Can SMCI Recover Amid +40% Fall?

Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength

Boudreau said overseas speech is expected to beryllium a tailwind of astir 1% to full-year reported income (including an expected favorable interaction of astir 3% successful the archetypal quarter). Abbott besides forecast an adjusted taxation complaint of 15% to 16%.

During Q&A, Ford addressed wherefore the top-line midpoint was somewhat beneath anterior statement helium referenced from the October call, attributing the alteration chiefly to the near-term outlook for nutrition, portion reiterating that overmuch of the portfolio is sustaining precocious single-digit maturation oregon accelerating. Ford besides said Abbott is not baking imaginable U.S. reimbursement enlargement for non-insulin CGM users into guidance, describing it arsenic an upside accidental if it materializes.